{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:56:34Z","timestamp":1773730594916,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T00:00:00Z","timestamp":1280880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T00:00:00Z","timestamp":1280880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1038\/npp.2010.111","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T15:34:06Z","timestamp":1280936046000},"page":"2367-2377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial"],"prefix":"10.1038","volume":"35","author":[{"given":"Wolfgang","family":"Gaebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"de Arce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rouillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Smeraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,4]]},"reference":[{"key":"BFnpp2010111_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2008.09.007","volume":"107","author":"FJ Acosta","year":"2009","unstructured":"Acosta FJ, Bosch E, Sarniento G, Juanes N, Caballero-Hidalgo A, Mayans T (2009). Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS(R)) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 107: 213\u2013217.","journal-title":"Schizophr Res"},{"key":"BFnpp2010111_CR2","unstructured":"American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC."},{"key":"BFnpp2010111_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76: 247\u2013265.","journal-title":"Schizophr Res"},{"key":"BFnpp2010111_CR4","first-page":"233","volume":"7","author":"G Chouinard","year":"1980","unstructured":"Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980). Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7: 233.","journal-title":"Can J Neurol Sci"},{"key":"BFnpp2010111_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1742-1241.2008.01900.x","volume":"63","author":"L Citrome","year":"2009","unstructured":"Citrome L (2009). Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 63: 140\u2013150.","journal-title":"Int J Clin Pract"},{"key":"BFnpp2010111_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.schres.2008.11.017","volume":"108","author":"L Citrome","year":"2009","unstructured":"Citrome L, Reist C, Palmer L, Montejano L, Lenhart G, Cuffel B et al (2009). Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 108: 238\u2013244.","journal-title":"Schizophr Res"},{"key":"BFnpp2010111_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJMoa002028","volume":"346","author":"JG Csernansky","year":"2002","unstructured":"Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16\u201322.","journal-title":"N Engl J Med"},{"key":"BFnpp2010111_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","volume":"159","author":"CR Dolder","year":"2002","unstructured":"Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159: 103\u2013108.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2010111_CR9","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.clinthera.2008.12.020","volume":"30","author":"R Emsley","year":"2008","unstructured":"Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J (2008). Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 30: 2378\u20132386.","journal-title":"Clin Ther"},{"key":"BFnpp2010111_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1744-859X-6-3","volume":"6","author":"GM Gharabawi","year":"2007","unstructured":"Gharabawi GM, Gearhart NC, Lasser RA, Mahmoud RA, Zhu Y, Mannaert E et al (2007). Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 6: 3.","journal-title":"Ann Gen Psychiatry"},{"key":"BFnpp2010111_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4088\/JCP.v66n0515","volume":"66","author":"ID Glick","year":"2005","unstructured":"Glick ID, Marder SR (2005). Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 66: 638\u2013641.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2010111_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.4088\/JCP.v68n0804","volume":"68","author":"PD Harvey","year":"2007","unstructured":"Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM (2007). Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry 68: 1186\u20131194.","journal-title":"J Clin Psychiatry"},{"issue":"12 Suppl 14","key":"BFnpp2010111_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852900025852","volume":"11","author":"JM Kane","year":"2006","unstructured":"Kane JM (2006). Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 11 (12 Suppl 14): 1\u20137.","journal-title":"CNS Spectr"},{"issue":"Suppl 17","key":"BFnpp2010111_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1092852900026304","volume":"12","author":"JM Kane","year":"2007","unstructured":"Kane JM (2007). Treatment adherence and long-term outcomes. CNS Spectr 12 (Suppl 17): 21\u201326.","journal-title":"CNS Spectr"},{"key":"BFnpp2010111_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.pnpbp.2008.03.012","volume":"32","author":"B Kim","year":"2008","unstructured":"Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E et al (2008). Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 32: 1231\u20131235.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 5","key":"BFnpp2010111_CR16","first-page":"3","volume":"67","author":"S Leucht","year":"2006","unstructured":"Leucht S, Heres S (2006). Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 (Suppl 5): 3\u20138.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2010111_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","volume":"79","author":"S Leucht","year":"2005","unstructured":"Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005). What does the PANSS mean? Schizophr Res 79: 231\u2013238.","journal-title":"Schizophr Res"},{"key":"BFnpp2010111_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000101366","volume":"40","author":"M Linden","year":"2007","unstructured":"Linden M, Godemann F (2007). The differentiation between \u201clack of insight\u201d and \u201cdysfunctional health beliefs\u201d in schizophrenia. Psychopathology 40: 236\u2013241.","journal-title":"Psychopathology"},{"key":"BFnpp2010111_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.psychres.2007.07.012","volume":"161","author":"P Llorca","year":"2008","unstructured":"Llorca P (2008). Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 161: 235\u2013247.","journal-title":"Psychiatry Res"},{"key":"BFnpp2010111_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1055\/s-2003-39985","volume":"36","author":"W L\u00f6ffler","year":"2003","unstructured":"L\u00f6ffler W, Kilian R, Toumi M, Angermeyer MC (2003). Schizophrenic patients\u2019 subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 36: 105\u2013112.","journal-title":"Pharmacopsychiatry"},{"key":"BFnpp2010111_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hup.1116","volume":"25","author":"S Madhusoodanan","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C (2010). Hyperprolactinemia associated with psychotropics\u2014a review. Hum Psychopharmacol 25: 281\u2013297.","journal-title":"Hum Psychopharmacol"},{"key":"BFnpp2010111_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1185\/03007990903149306","volume":"25","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS (2009a). Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 25: 2197\u20132206.","journal-title":"Curr Med Res Opin"},{"key":"BFnpp2010111_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","volume":"24","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z et al (2009b). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24: 287\u2013296.","journal-title":"Eur Psychiatry"},{"key":"BFnpp2010111_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1517\/14740330902835493","volume":"8","author":"CU Pae","year":"2009","unstructured":"Pae CU (2009). A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 8: 373\u2013386.","journal-title":"Expert Opin Drug Saf"},{"key":"BFnpp2010111_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.schres.2006.03.027","volume":"85","author":"SG Potkin","year":"2006","unstructured":"Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF et al (2006). A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 85: 254\u2013265.","journal-title":"Schizophr Res"},{"key":"BFnpp2010111_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/pds.1559","volume":"17","author":"Q Said","year":"2008","unstructured":"Said Q, Gutterman EM, Kim MS, Firth SD, Whitehead R, Brixner D (2008). Somnolence effects of antipsychotic medications and the risk of unintentional injury. Pharmacoepidemiol Drug Saf 17: 354\u2013364.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 16","key":"BFnpp2010111_CR27","first-page":"14","volume":"64","author":"NR Schooler","year":"2003","unstructured":"Schooler NR (2003). Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 64 (Suppl 16): 14\u201317.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2010111_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00023210-200822010-00004","volume":"22","author":"A Sparshatt","year":"2008","unstructured":"Sparshatt A, Jones S, Taylor D (2008). Quetiapine. Dose-response relationship in schizophrenia. CNS Drugs 22: 49\u201368.","journal-title":"CNS Drugs"},{"issue":"Suppl","key":"BFnpp2010111_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1192\/bjp.195.52.s13","volume":"52","author":"D Taylor","year":"2009","unstructured":"Taylor D (2009). Psychopharmcology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 52 (Suppl): 13\u201319.","journal-title":"Br J Psychiatry"},{"key":"BFnpp2010111_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.psychres.2004.07.014","volume":"141","author":"K Yamada","year":"2006","unstructured":"Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraishi C, Yamauchi K et al (2006). Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res 141: 61\u201369.","journal-title":"Psychiatry Res"}],"updated-by":[{"DOI":"10.1038\/npp.2010.206","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T00:00:00Z","timestamp":1289952000000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2010111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2010111","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2010111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:21:39Z","timestamp":1684455699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2010111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,4]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["BFnpp2010111"],"URL":"https:\/\/doi.org\/10.1038\/npp.2010.111","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/npp.2010.206","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,4]]},"assertion":[{"value":"24 November 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W Gaebel has received research grants from, and served as consultant, advisor, and speaker for AstraZeneca, Janssen-Cilag, Eli Lilly, Servier, Lundbeck, and Wyeth Pharma; A Schreiner is a full employee of Janssen-Cilag, Medical Affairs EMEA, Germany; P Bergmans is a full employee of Janssen-Cilag, Medical Affairs, Clinical Research Information Group, the Netherlands; R de Arce has received research grants from, and served as consultant, advisor, or speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Novartis, Bristol, Pfizer, sanofi-aventis, and UCB Pharma; F Rouillon has received grants from, and served as consultant, advisor, and speaker for Bristol-Myers Squibb, sanofi-aventis, Servier, Lundbeck, Eli Lilly, Wyeth, and Biocodex; J Cordes has received grants from, and served as a consultant, advisor, and speaker for Pfizer, Lundbeck, AstraZeneca, Eli Lilly, Janssen-Cilag, Bristol-Myers Squibb, Alpine Biomed, and Servier; L Eriksson served as consultant, advisor, and speaker for Janssen-Cilag, AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; E Smeraldi served as consultant, advisor, and speaker for Janssen-Cilag, InnovaPharma, and Wyeth.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}